Advertisement

Active Care Management Supported by Home Telemonitoring in Veterans With Type 2 Diabetes

The DiaTel randomized controlled trial

  1. Roslyn A. Stone, PHD1,2,
  2. R. Harsha Rao, MD3,4,
  3. Mary Ann Sevick, SCD2,4,5,6,
  4. Chunrong Cheng, PHD1,2,
  5. Linda J. Hough, MPH7,
  6. David S. Macpherson, MD4,8,
  7. Carol M. Franko, CRNP5,
  8. Rebecca A. Anglin, RN3,
  9. D. Scott Obrosky, MS4 and
  10. Frederick R. DeRubertis, MD3,4
  1. 1Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania;
  2. 2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania;
  3. 3Medical Specialty Service Line, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania;
  4. 4Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;
  5. 5Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania;
  6. 6Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania;
  7. 7Veterans Research Foundation of Pittsburgh, Pittsburgh, Pennsylvania;
  8. 8VISN 4 Healthcare Network, Pittsburgh, Pennsylvania.
  1. Corresponding author: Frederick R. DeRubertis, frederick.derubertis{at}va.gov.

Abstract

OBJECTIVE We compared the short-term efficacy of home telemonitoring coupled with active medication management by a nurse practitioner with a monthly care coordination telephone call on glycemic control in veterans with type 2 diabetes and entry A1C ≥7.5%.

RESEARCH DESIGN AND METHODS Veterans who received primary care at the VA Pittsburgh Healthcare System from June 2004 to December 2005, who were taking oral hypoglycemic agents and/or insulin for ≥1 year, and who had A1C ≥7.5% at enrollment were randomly assigned to either active care management with home telemonitoring (ACM+HT group, n = 73) or a monthly care coordination telephone call (CC group, n = 77). Both groups received monthly calls for diabetes education and self-management review. ACM+HT group participants transmitted blood glucose, blood pressure, and weight to a nurse practitioner using the Viterion 100 TeleHealth Monitor; the nurse practitioner adjusted medications for glucose, blood pressure, and lipid control based on established American Diabetes Association targets. Measures were obtained at baseline, 3-month, and 6-month visits.

RESULTS Baseline characteristics were similar in both groups, with mean A1C of 9.4% (CC group) and 9.6% (ACM+HT group). Compared with the CC group, the ACM+HT group demonstrated significantly larger decreases in A1C at 3 months (1.7 vs. 0.7%) and 6 months (1.7 vs. 0.8%; P < 0.001 for each), with most improvement occurring by 3 months.

CONCLUSIONS Compared with the CC group, the ACM+HT group demonstrated significantly greater reductions in A1C by 3 and 6 months. However, both interventions improved glycemic control in primary care patients with previously inadequate control.

Footnotes

  • Clinical trial reg. no. NCT00245882, www.clinicaltrials.gov.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received June 2, 2009.
    • Accepted December 1, 2009.
| Table of Contents

This Article

  1. Diabetes Care March 2010 vol. 33 no. 3 478-484
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. dc09-1012v1
    2. 33/3/478 most recent
Advertisement